Diurnal Group PLC Director Dealings (2593I)
07 August 2019 - 12:04PM
UK Regulatory
TIDMDNL
RNS Number : 2593I
Diurnal Group PLC
07 August 2019
7 August 2019
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces the following Directors' dealings undertaken
for tax planning purposes:
Martin Whitaker, Chief Executive Officer, sold 44,810 Ordinary
Shares at a price of 37 pence per Ordinary Share and his ISA
purchased 44,810 Ordinary Shares at a price of 37.1 pence per
Ordinary Share.
Additionally, Martin Whitaker purchased a total of 15,104
Ordinary Shares at 38 pence per share, to be held in pension
schemes for the beneficial interest of his dependent children.
Following the transactions, the total beneficial interest of
Martin Whitaker and his connected parties is 120,643 Ordinary
Shares, representing 0.14% of the total voting rights.
Details of the full notifications received by the Company are
set out below:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Martin Whitaker
------------------------------ ---------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------ ---------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------ ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Diurnal Group plc
------------------------------ ---------------------------------------------
b) LEI 213800I2HNUNZN1LDH29
------------------------------ ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in
financial instrument, Diurnal Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Sale and purchase of ordinary shares
------------------------------ ---------------------------------------------
c) Price(s) and volume(s)
-------------------- -----------
Price(s) Volume(s)
-------------------- -----------
Sell 37p 44,810
Purchase 37.1p 44,810
-------------------------------------------------------------- -----------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 6 August 2019
------------------------------ ---------------------------------------------
f) Place of the transaction XLON
------------------------------ ---------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Martin Whitaker and dependent children
------------------------------------- ----------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------
a) Name Diurnal Group plc
------------------------------------- ----------------------------------------------
b) LEI 213800I2HNUNZN1LDH29
------------------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in
financial instrument, Diurnal Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Purchase of ordinary shares for the
beneficial interest of his children
------------------------------------- ----------------------------------------------
c) Price(s) and volume(s)
--------------------- --------------------
Price(s) Volume(s)
--------------------- --------------------
Buy 38p 15,104
---------------------------------------------------------------- --------------------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 7 August 2019
------------------------------------- ----------------------------------------------
f) Place of the transaction XLON
------------------------------------- ----------------------------------------------
For further information, please visit www.diurnal.co.uk or contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0) 20 7886
and Joint Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: James Stearns
+44 (0)20 7894
Cantor Fitzgerald Europe (Joint Broker) 7000
Corporate Finance: Phil Davies, Will Goode,
Michael Boot
Healthcare Equity Sales: Andrew Keith
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company
developing high quality products for the global market for the
life-long treatment of chronic endocrine conditions, including
Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its
expertise and innovative research activities focus on
circadian-based endocrinology to yield novel product candidates in
the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFIITIIDIIA
(END) Dow Jones Newswires
August 07, 2019 06:04 ET (10:04 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Diurnal (LSE:DNL)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
